Legal Representation
Attorney
John Pickerill
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 29, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Dec 29, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Dec 27, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jun 24, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Dec 26, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 24, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Dec 24, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 12, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 12, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 23, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 3, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 2, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 2, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 2, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 26, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 26, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 26, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 26, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 21, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Aug 12, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 18, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
First Use Anywhere:
Jul 25, 2024
First Use in Commerce:
Jul 25, 2024
Additional Information
Design Mark
The mark consists of a set of colored boxes and one circle ranging in color from blue to purple to green, and in size from large to small starting on the right side and arching over the letters "DUV" in the stylized word element "DUVYZAT" in blue, with the final design element being a green circle above the letter "V".
Color Claim
The colos blue, purple, and green are claimed as a feature of the mark.
Translation
The wording "DUVYZAT" has no meaning in a foreign language.
Classification
International Classes
005